Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough

Exclusion Criteria

• •Previous exposure to taplucainium (formerly NTX-1175) or known allergy or hypersensitivity to taplucainium, its excipients/metabolites, or related compounds.
• •Participants who are currently participating in another drug or device clinical study
• •Participants who have participated in an Acute or Chronic Cough investigational study within 60 days before the start of the Screening.
• •Current diagnosis of chronic obstructive pulmonary disease, bronchiectasis, unexplained pulmonary fibrosis, hemoptysis, bronchial asthma, or other pulmonary disease.
• •Respiratory tract infection within 4 weeks of Screening or during screening period.
• •Any female who is pregnant or lactating or wishing to become pregnant.
• •Donation of \> 1 Unit (450 milliliter or more) of blood within 60 days prior to the first dosing.
• •Alcohol or drug use disorder within the past 2 years.
• •Current smoker/vaper or individuals who have given up smoking within the past 6 months of screening, and/or those with \>20 pack-year smoking history.
• •Current opiate/opioid use or medical history of opiate/opioid use disorder.
• •History of concurrent malignancy or recurrence of malignancy in the last 2 years.
• •Body Mass Index of ≥40 kg/m2.
• •Positive results for human immunodeficiency virus, hepatitis B, or hepatitis C virus.
• •Unable to refrain from the use of medications and treatments that can impact cough during the study.
• •Have clinically significant history or evidence of poorly controlled cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, neurological, immunological, or psychiatric disorder(s).